Download PDF
J Reconstr Microsurg 2008; 24(3): 189-195
DOI: 10.1055/s-2008-1076085
© Thieme Medical Publishers

Anti-CD40L Monoclonal Antibody Treatment Induces Long-Term, Tissue-Specific, Immunologic Hyporesponsiveness to Peripheral Nerve Allografts

Anil K. Mungara1 , David L. Brown1 , D. Keith Bishop2 , Sherri Y. Wood2 , Paul S. Cederna1 , 3
  • 1Section of Plastic and Reconstructive Surgery, University of Michigan, Ann Arbor, MI
  • 2Section of General Surgery, Deparment of Surgery and Graduate Program in Immunology, University of Michigan, Ann Arbor, MI
  • 3Institute of Gerontology, University of Michigan, Ann Arbor, MI
Further Information

Publication History

Publication Date:
05 May 2008 (online)

    Permissions and Reprints

ABSTRACT

The CD40/CD40L costimulatory pathway plays a crucial role in allograft rejection. The purpose of this study was to determine the effectiveness of anti-CD40L monoclonal antibody (mAb) treatment as a method to induce long-term, tissue-specific, immunologic hyporesponsiveness to peripheral nerve allografts. Sciatic nerve allografts were performed from BALB/c donor mice into C57BL/6 recipients. Anti-CD40L mAb (1 mg) was administered intraperitoneally to recipient mice on postoperative days 0, 1, and 2. After a 14-, 28-, or 60-day recovery period, the mice were rechallenged with either a BALB/c cardiac or peripheral nerve allograft. Rejection was assessed by measuring the production of interferon gamma (IFN-γ), interleukin (IL)-2, -4, and -5, and alloantibodies immunoglobulin (Ig) M and IgG. IFN-γ, IL-2, IL-4, IL-5, IgM, and IgG responses were much lower in the anti-CD40L mAb group compared with controls. Nerve allograft and nerve isograft rechallenge 60 days following the original nerve allotransplantation produced low cytokine responses, whereas cardiac allograft rechallenge produced high cytokine production, indicative of acute rejection. Short-term anti-CD40L treatment may cause long-term, tissue-specific, immunologic hyporesponsiveness. This may allow time for native axons to traverse the transplanted nerve allograft and replace the graft with autogenous peripheral nerve tissue.

KEYWORDS

Nerve allograft - anti-CD40L mAb - MR1

REFERENCES

  • 1 Mackinnon S E. Nerve allotransplantation following severe tibial nerve injury. Case report.  J Neurosurg. 1996;  84 671-676
    PubMedGoogle Scholar
  • 2 Mackinnon S E, Doolabh V B, Novak C B, Trulock E P. Clinical outcome following nerve allograft transplantation.  Plast Reconstr Surg. 2001;  107 1419-1429
    CrossrefPubMedGoogle Scholar
  • 3 Hare G M, Evans P J, Mackinnon S E et al.. Effect of cold preservation on lymphocyte migration into peripheral nerve allografts in sheep.  Transplantation. 1993;  56 154-162
    PubMedGoogle Scholar
  • 4 Sondell M, Lundborg G, Kanje M. Regeneration of rat sciatic nerve into allografts made acellular through chemical extraction.  Brain Res. 1998;  795 44-54
    CrossrefPubMedGoogle Scholar
  • 5 MacKinnon S E, Hudson A R. Clinical application of peripheral nerve transplantation.  Plast Reconstr Surg. 1992;  90 695-699
    PubMedGoogle Scholar
  • 6 Lassner F, Schaller E, Steinhoff G, Wonigeit K, Walter G F, Berger A. Cellular mechanisms of rejection and regeneration in peripheral nerve allografts.  Transplantation. 1989;  48 386-392
    CrossrefPubMedGoogle Scholar
  • 7 Midha R, Mackinnon S E, Becker L E. The fate of Schwann cells in peripheral nerve allografts.  J Neuropathol Exp Neurol. 1994;  53 316-322
    PubMedGoogle Scholar
  • 8 Atchabahian A, Genden E M, Mackinnon S E, Doolabh V B, Hunter D A. Regeneration through long nerve grafts in the swine model.  Microsurgery. 1998;  18 379-382
    CrossrefPubMedGoogle Scholar
  • 9 Best T J, Mackinnon S E, Midha R, Hunter D A, Evans P J. Revascularization of peripheral nerve autografts and allografts.  Plast Reconstr Surg. 1999;  104 152-160
    CrossrefPubMedGoogle Scholar
  • 10 Trumble T E, Shon F G. The physiology of nerve transplantation.  Hand Clin. 2000;  16 105-122
    PubMedGoogle Scholar
  • 11 Ansselin A D, Pollard J D. Immunopathological factors in peripheral nerve allograft rejection: quantification of lymphocyte invasion and major histocompatibility complex expression.  J Neurol Sci. 1990;  96 75-78
    CrossrefPubMedGoogle Scholar
  • 12 Rovak J M, Bishop D K, Boxer L K, Wood S C, Mungara A K, Cederna P S. Peripheral nerve transplantation: the role of chemical acellularization in eliminating allograft antigenicity.  J Reconstr Microsurg. 2005;  21 207-213
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Kirk A D, Harlan D M, Armstrong N N et al.. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.  Proc Natl Acad Sci U S A. 1997;  94 8789-8794
    CrossrefPubMedGoogle Scholar
  • 14 Elster E A, Blair P J, Kirk A D. Potential of co-stimulation based therapies for composite tissue allotransplantation.  Microsurgery. 2000;  20 430-434
    CrossrefPubMedGoogle Scholar
  • 15 Larsen C P, Elwood E T, Alexander D Z et al.. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.  Nature. 1996;  381 434-438
    CrossrefPubMedGoogle Scholar
  • 16 Pierson R N, Chang A C, Blum M G et al.. Prolongation of primate cardiac allograft survival by treatment with anti-CD40 ligand (CD154) antibody.  Transplantation. 1999;  68 1800-1805
    CrossrefPubMedGoogle Scholar
  • 17 Durie F H, Foy T M, Masters S R, Laman J D, Noelle R J. The role of CD40 in the regulation of humoral and cell-mediated immunity.  Immunol Today. 1994;  15 406-411
    CrossrefPubMedGoogle Scholar
  • 18 Yamada A, Sayegh M H. The CD154-CD40 costimulatory pathway in transplantation.  Transplantation. 2002;  73 S36-S39
    CrossrefPubMedGoogle Scholar
  • 19 Jones N D, Van Maurik A, Hara M et al.. CD40-CD40 ligand independent activation of CD8 + T cells can trigger allograft rejection.  J Immunol. 2000;  165 1111-1118
    PubMedGoogle Scholar
  • 20 Sayegh M H, Turka L A. The role of T-cell costimulatory activation pathways in transplant rejection.  N Engl J Med. 1998;  338 1813-1821
    CrossrefPubMedGoogle Scholar
  • 21 Sun H, Subbotin V, Chen C et al.. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody.  Transplantation. 1997;  64 1838-1843
    CrossrefPubMedGoogle Scholar
  • 22 Kirk A D, Burkly L C, Batty D S et al.. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates.  Nat Med. 1999;  5 686-693
    PubMedGoogle Scholar
  • 23 Kenyon N S, Chatzipetrou M, Masetti M et al.. Long term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154.  Proc Natl Acad Sci U S A. 1999;  96 8132-8137
    CrossrefPubMedGoogle Scholar
  • 24 Nathan M J, Yin D, Eichwald E J, Bishop D K. The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells.  Am J Transplant. 2002;  2 323-332
    CrossrefPubMedGoogle Scholar
  • 25 Guillot C, Guillonneau C, Mathieu P et al.. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long term heart allograft survival and donor specific hyporesponsiveness, but does not prevent chronic rejection.  J Immunol. 2002;  168 1600-1609
    PubMedGoogle Scholar
  • 26 Matesic D, Lehmann P V, Heeger P S. High resolution characterization of cytokine producing alloreactivity in naïve and allograft primed mice.  Transplantation. 1998;  65 906-914
    CrossrefPubMedGoogle Scholar
  • 27 Brown D L, Bishop D K, Wood S Y, Cederna P S. Short-term anti-CD40 ligand costimulatory blockade induces tolerance to peripheral nerve allografts, resulting in improved skeletal muscle function.  Plast Reconstr Surg. 2006;  117 2250-2258
    CrossrefPubMedGoogle Scholar
  • 28 Shepherd D M, Kerkvliet N I. Disruption of CD154:CD40 blocks regeneration of allograft immunity without affecting APC activation.  J Immunol. 1999;  163 2470-2477
    PubMedGoogle Scholar
  • 29 Bishop D K, Wood S, Eichwald E, Orosz C. Immunobiology of allograft rejection in the absence of INF-γ: CD8 + effector cells develop independently of CD4 + cells and CD40-CD40 ligand interactions.  J Immunol. 2001;  166 3248-3255
    PubMedGoogle Scholar
  • 30 Azuma H, Chandraker A, Nadeau K. Blockade of T cell costimulation prevents development of experimental chronic allograft rejection.  Proc Natl Acad Sci U S A. 1996;  93 12439-12444
    CrossrefPubMedGoogle Scholar
  • 31 Graca L, Honey K, Adams E, Cobbold S, Waldmann H. Cutting edge: anti-CD154 therapeutic antibodies induce infectious tolerance.  J Immunol. 2000;  165 4783-4786
    PubMedGoogle Scholar
  • 32 Li Y, Li X C, Zheng A et al.. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.  Nat Med. 1999;  5 1298-1302
    PubMedGoogle Scholar
  • 33 Wells A D, Li X C, Li Y et al.. Requirement for T cell apoptosis in the induction of peripheral transplantation tolerance.  Nat Med. 1999;  5 1303-1307
    CrossrefPubMedGoogle Scholar
  • 34 Iwakoshi N N, Mordes J P, Markees T G, Phillips N E, Rossini A A, Greiner D L. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8 + T cells and prolonged graft survival in a CTA4-dependent manner.  J Immunol. 2000;  164 512-521
    PubMedGoogle Scholar
  • 35 Ensminger S M, Witzke O, Spriewald B M et al.. CD8 + T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade.  Transplantation. 2000;  69 2609-2612
    CrossrefPubMedGoogle Scholar
  • 36 Evans P J, Mackinnon S E, Midha R et al.. Regeneration across cold preserved peripheral nerve allografts.  Microsurgery. 1999;  19 115-127
    CrossrefPubMedGoogle Scholar
  • 37 Bain J R. Peripheral nerve and neuromuscular allotransplantation: current status.  Microsurgery. 2000;  20 384-388
    CrossrefPubMedGoogle Scholar

Paul S CedernaM.D. F.A.C.S. 

2130 Taubman Center

1500 E. Medical Center Drive, Ann Arbor, MI 48109-0340

      >